Related Experiment Video
Updated: Jul 14, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Endothelins in health and disease
1Section of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Insights
Endothelin-1 (ET-1) is a key peptide in cardiovascular regulation and disease. While ET-1 antagonists show promise for pulmonary hypertension, their efficacy in heart failure requires further investigation.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelins (ETs) are potent vasoconstrictor peptides with diverse physiological roles.
- Endothelin-1 (ET-1), the primary cardiovascular isoform, acts via ET(A) and ET(B) receptors.
- ET-1 contributes to basal vascular tone and is implicated in various cardiovascular diseases.
Purpose of the Study:
- To review the role of ET-1 in cardiovascular function and disease.
- To evaluate the therapeutic potential of ET-1 antagonists.
Main Methods:
- Literature review of endothelin physiology and pharmacology.
- Analysis of clinical trial data for ET-1 antagonists in cardiovascular diseases.
Main Results:
- ET-1 antagonists are effective in treating primary pulmonary hypertension.
- Clinical trials indicate disappointing results for ET-1 antagonists in heart failure.
Conclusions:
- The endothelin system is a viable therapeutic target for specific cardiovascular conditions.
- Further clinical trials are necessary to ascertain the benefits of ET system modulation in other diseases.
Abstract:
Endothelins are powerful vasoconstrictor peptides that also play numerous other roles. The endothelin (ET) family consists of three peptides produced by a variety of tissues. Endothelin-1 (ET-1) is the principal isoform produced by the endothelium in the human cardiovascular system, and it exerts its actions through binding to specific receptors, the so-called type A (ET(A)) and type B (ET(B)) receptors. ET-1 is primarily a locally acting paracrine substance that appears to contribute to the maintenance of basal vascular tone. It is also activated in several diseases, including congestive heart failure, arterial hypertension, atherosclerosis, endothelial dysfunction, coronary artery diseases, renal failure, cerebrovascular disease, pulmonary arterial hypertension, and sepsis. Thus, ET-1 antagonists are promising new agents. They have been shown to be effective in the management of primary pulmonary hypertension, but disappointing in heart failure. Clinical trials are needed to determine whether manipulation of the ET system will be beneficial in other diseases.
More Related Videos
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
09:47Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography
Published on: August 12, 2022
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Overview of the Vascular System
Acute Inflammation III: Local and Systemic Effects
Hypertension II: Pathophysiology
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal